diagnosis of alzheimers disease based on disease-specific autoantibody profiles in human sera阿尔茨海默病的诊断基于特定疾病在人类血清自身抗体的概要文件.pdfVIP

Diagnosis of Alzheimer’s Disease Based on Disease- Specific Autoantibody Profiles in Human Sera 1. 2,3. 2 1 3 Eric Nagele , Min Han , Cassandra DeMarshall , Benjamin Belinka , Robert Nagele * 1 Durin Technologies, Inc., New Brunswick, New Jersey, United States of America, 2 Graduate School of Biomedical Sciences, School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America, 3 New Jersey Institute for Successful Aging, School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America Abstract After decades of Alzheimer’s disease (AD) research, the development of a definitive diagnostic test for this disease has remained elusive. The discovery of blood-borne biomarkers yielding an accurate and relatively non-invasive test has been a primary goal. Using human protein microarrays to characterize the differential expression of serum autoantibodies in AD and non-demented control (NDC) groups, we identified potential diagnostic biomarkers for AD. The differential significance of each biomarker was evaluated, resulting in the selection of only 10 autoantibody biomarkers that can effectively differentiate AD sera from NDC sera with a sensitivity of 96.0% and specificity of 92.5%. AD sera were also distinguishable from sera obtained from patients with Parkinson’s disease and breast cancer with accuracies of 86% and 92%, respectively. Results demonstrate that serum autoantibodies can be used effectively as highly-specific and accurate biomarkers to diagnose AD throughout the course of the disease. Citation: Nagele E, Han M, DeMarshall C, Belinka B, Nagele R (2